Diplomat Pharmacy, Inc. (NYSE:DPLO) CFO Atul Kavthekar purchased 2,000 shares of Diplomat Pharmacy stock in a transaction that occurred on Monday, November 20th. The shares were bought at an average cost of $15.00 per share, with a total value of $30,000.00. Following the completion of the transaction, the chief financial officer now directly owns 2,000 shares of the company’s stock, valued at approximately $30,000. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of Diplomat Pharmacy, Inc. (NYSE DPLO) opened at $15.94 on Tuesday. Diplomat Pharmacy, Inc. has a 12-month low of $12.25 and a 12-month high of $21.99. The company has a market capitalization of $1,070.00, a PE ratio of 19.48, a P/E/G ratio of 2.70 and a beta of 0.74. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.34 and a quick ratio of 0.82.
Diplomat Pharmacy (NYSE:DPLO) last announced its earnings results on Monday, November 6th. The company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.16 billion. During the same quarter in the previous year, the business earned $0.21 EPS. The company’s revenue was down 4.8% compared to the same quarter last year. equities analysts anticipate that Diplomat Pharmacy, Inc. will post 0.85 earnings per share for the current fiscal year.
A number of equities analysts have recently weighed in on DPLO shares. Robert W. Baird lowered Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $24.00 to $18.00 in a research note on Thursday, November 16th. BidaskClub lowered Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Needham & Company LLC raised their price objective on Diplomat Pharmacy from $23.75 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. Leerink Swann raised their price objective on Diplomat Pharmacy from $16.00 to $20.00 and gave the stock a “market perform” rating in a research note on Tuesday, November 7th. Finally, Mizuho raised their price objective on Diplomat Pharmacy from $16.00 to $20.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $19.39.
Several hedge funds and other institutional investors have recently made changes to their positions in DPLO. JPMorgan Chase & Co. lifted its stake in Diplomat Pharmacy by 73.1% in the first quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock valued at $116,000 after purchasing an additional 3,056 shares during the last quarter. State of Alaska Department of Revenue lifted its position in shares of Diplomat Pharmacy by 80.0% during the second quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock worth $127,000 after acquiring an additional 3,833 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Diplomat Pharmacy by 46.7% during the second quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after buying an additional 2,794 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Diplomat Pharmacy during the third quarter worth about $191,000. Finally, Municipal Employees Retirement System of Michigan boosted its holdings in shares of Diplomat Pharmacy by 4.9% during the second quarter. Municipal Employees Retirement System of Michigan now owns 10,250 shares of the company’s stock worth $152,000 after purchasing an additional 480 shares during the period. Hedge funds and other institutional investors own 67.74% of the company’s stock.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.